SEC Form 4 · accession 0001179110-19-003315
Blueprint Medicines Corp · BPMC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kate Haviland
Officer — Chief Operating Officer
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 5:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597264
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 1, 2019 | M | 14,144 | $16.28 | A | 20,018 | D | |
| Common Stock | Mar 1, 2019 | M | 7,500 | $36.05 | A | 27,518 | D | |
| Common StockF3 | Mar 1, 2019 | S | 21,644 | $85.05 | D | 5,874 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $86.60 | Mar 1, 2019 | A | 32,500 | A | — | Mar 1, 2029 | Common Stock | 32,500 | 32,500 | D |
| Restricted Stock UnitsF5,F6 | — | Mar 1, 2019 | A | 8,750 | A | — | — | Common Stock | 8,750 | 8,750 | D |
| Stock Option (Right to Buy)F7 | $16.28 | Mar 1, 2019 | M | 14,144 | D | — | Feb 1, 2026 | Common Stock | 14,144 | 33,495 | D |
| Stock Option (Right to Buy)F8 | $36.05 | Mar 1, 2019 | M | 7,500 | D | — | Feb 16, 2027 | Common Stock | 7,500 | 24,000 | D |
Explanation of responses
- F1The exercises reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- F2The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Exchange Act.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F4This option vests with respect to 1/48th of the shares underlying the option on April 1, 2019 and as to an additional 1/48th of the shares underlying the option each month thereafter.
- F5Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F6The restricted stock units vest in four equal annual installments on March 1, 2020, 2021, 2022 and 2023.
- F7This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.
- F8This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.